Literature DB >> 16462705

Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).

Vincenzo De Sanctis1, Androulla Eleftheriou, Cristina Malaventura.   

Abstract

Although numerous studies are available in the literature on endocrine complications in thalassaemia, little is known about this subject in developing countries. Therefore, an international multicenter study was conducted in a large series of children and adolescents with beta thalassaemia major in order to obtain more information on the prevalence of short stature and endocrine complications in different areas of the world and to elucidate the problems that must be dealt with in the future. A questionnaire was sent to 29 Centres treating a total of 3817 beta thalassaemia major patients. Thirty-six per cent of patients were over the age of 16 years. Short stature was present in 31.1% of males and 30.5% of females, and the prevalence of growth hormone deficiency was 7.9% in males and 8.8% in females. Lack of pubertal changes was the most common endocrine complication (40.5%) followed by hypoparathyroidism (6.9%), impaired glucose tolerance (6.5%), insulin-dependent diabetes mellitus (3.2%) and primary hypothyroidism (3.2%). The prevalence of endocrine complications differed among centres, particularly for growth hormone deficiency, hypoparathyroidism and hypothyroidism. Compliance to chelation therapy was poor in 51% of patients and serum liver enzymes were high in 65% of patients. Since several endocrine glands may be affected in patients with thalassaemia major, and their life expectancy is now much longer, it is important that physicians be aware of the endocrine abnormalities that may develop. Therefore, periodic evaluation of these problems should be carried out in thalassaemic patients with iron overload, particularly after the age of 11 years. In conclusion, since iron overload and liver damage seem to be the most important factors responsible for endocrine complications, adequate compliance to chelation therapy and rigid precautions against liver infections are imperative.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16462705

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  45 in total

1.  Bone age estimation and prediction of final height in patients with beta-thalassaemia major: a comparison between the two most common methods.

Authors:  Athanasios Christoforidis; Maria Badouraki; George Katzos; Miranda Athanassiou-Metaxa
Journal:  Pediatr Radiol       Date:  2007-10-19

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  Prevalence of growth and endocrine disorders in Malaysian children with transfusion-dependent thalassaemia.

Authors:  Khian Aun Tan; Su Han Lum; Abqariyah Yahya; Shekhar Krishnan; Muhammad Yazid Jalaludin; Way Seah Lee
Journal:  Singapore Med J       Date:  2018-12-17       Impact factor: 1.858

4.  Endocrine and metabolic disorders in β-thalassemiamajor patients.

Authors:  Fatemeh Saffari; Abolfazl Mahyar; Shabnam Jalilolgadr
Journal:  Caspian J Intern Med       Date:  2012

5.  Complications and treatment of patients with β-thalassemia in France: results of the National Registry.

Authors:  Isabelle Thuret; Corinne Pondarré; Anderson Loundou; Dominique Steschenko; Robert Girot; Dora Bachir; Christian Rose; Vincent Barlogis; Jean Donadieu; Mariane de Montalembert; Isabelle Hagege; Brigitte Pegourie; Claire Berger; Marguerite Micheau; Françoise Bernaudin; Thierry Leblanc; Laurence Lutz; Frédéric Galactéros; Marie-Claude Siméoni; Catherine Badens
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

6.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

7.  Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.

Authors:  Maria G Vogiatzi; Eric A Macklin; Felicia L Trachtenberg; Ellen B Fung; Angela M Cheung; Elliott Vichinsky; Nancy Olivieri; Melody Kirby; Janet L Kwiatkowski; Melody Cunningham; Ingrid A Holm; Martin Fleisher; Robert W Grady; Charles M Peterson; Patricia J Giardina
Journal:  Br J Haematol       Date:  2009-07-13       Impact factor: 6.998

8.  Endocrine Dysfunction in Diamond-Blackfan Anemia (DBA): A Report from the DBA Registry (DBAR).

Authors:  Amit Lahoti; Yael T Harris; Phyllis W Speiser; Evangelia Atsidaftos; Jeffrey M Lipton; Adrianna Vlachos
Journal:  Pediatr Blood Cancer       Date:  2015-10-23       Impact factor: 3.167

9.  Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Authors:  Saumya S Jamuar; Angeline H M Lai
Journal:  Ther Adv Hematol       Date:  2012-10

10.  Gradient-echo magnetic resonance imaging study of pancreatic iron overload in young Egyptian beta-thalassemia major patients and effect of splenectomy.

Authors:  Randa M Matter; Khalid E Allam; Amany M Sadony
Journal:  Diabetol Metab Syndr       Date:  2010-04-15       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.